Nov. 13 at 12:31 AM
$LYRA
Thanks AI.
Q3 25:
• Revenue:
$25K in Q3 (down 87% from
$195K YoY); YTD
$391K (down 70%). Mostly from winding down LianBio collab.
• Operating Expenses: Down 50% to
$6.3M in Q3. R&D dropped 31% to
$4.0M (post-trial wrap-up), G&A down 43% to
$2.2M. Minor restructuring credit this quarter vs. big charges last year.
• Net Loss:
$6.0M (
$3.38/sh) vs.
$11.9M (
$9.07/sh) YoY – a 50% improvement. YTD loss
$22M, down 73%.
• Balance Sheet: Cash at
$22.1M (down 46% YTD from
$40.6M). Total assets
$43.7M; liabilities
$48M, leading to
$4.3M stockholder deficit. Shares out: 1.64M (up slightly).
• Cash Runway: Now into Q3 2026 under current plan, but that doesn’t include funding a new trial (est.
$50-100M needed).
